Zurich Cantonal Bank’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.14M | Hold |
30,677
| – | – | ﹤0.01% | 1472 |
|
|
2026
Q1 | $973K | Buy |
+30,677
| New | +$836K | ﹤0.01% | 1449 |
|
|
2025
Q4 | – | Sell |
-22,800
| Closed | -$601K | – | 2758 |
|
|
2025
Q3 | $590K | Buy |
22,800
+3,740
| +20% | +$86.7K | ﹤0.01% | 1645 |
|
|
2025
Q2 | $388K | Buy |
19,060
+3,130
| +20% | +$60.9K | ﹤0.01% | 1811 |
|
|
2025
Q1 | $289K | Hold |
15,930
| – | – | ﹤0.01% | 1909 |
|
|
2024
Q4 | $403K | Buy |
15,930
+1,819
| +13% | +$49.4K | ﹤0.01% | 1759 |
|
|
2024
Q3 | $480K | Hold |
14,111
| – | – | ﹤0.01% | 1590 |
|
|
2024
Q2 | $522K | Buy |
14,111
+4,093
| +41% | +$154K | ﹤0.01% | 1467 |
|
|
2024
Q1 | $420K | Sell |
10,018
-2,014
| -17% | -$82.7K | ﹤0.01% | 1590 |
|
|
2023
Q4 | $477K | Buy |
12,032
+5,450
| +83% | +$160K | ﹤0.01% | 1532 |
|
|
2023
Q3 | $181K | Buy |
6,582
+1,746
| +36% | +$54.7K | ﹤0.01% | 2035 |
|
|
2023
Q2 | $164K | Hold |
4,836
| – | – | ﹤0.01% | 2052 |
|
|
2023
Q1 | $174K | Buy |
4,836
+1,053
| +28% | +$45.4K | ﹤0.01% | 1963 |
|
|
2022
Q4 | $169K | Hold |
3,783
| – | – | ﹤0.01% | 1926 |
|
|
2022
Q3 | $106K | Hold |
3,783
| – | – | ﹤0.01% | 2172 |
|
|
2022
Q2 | $102K | Sell |
3,783
-1,827
| -33% | -$53.1K | ﹤0.01% | 2226 |
|
|
2022
Q1 | $191K | Buy |
5,610
+1,459
| +35% | +$46.6K | ﹤0.01% | 1913 |
|
|
2021
Q4 | $160K | Hold |
4,151
| – | – | ﹤0.01% | 2220 |
|
|
2021
Q3 | $224K | Hold |
4,151
| – | – | ﹤0.01% | 1849 |
|
|
2021
Q2 | $139K | Buy |
4,151
+1,673
| +68% | +$45.9K | ﹤0.01% | 2049 |
|
|
2021
Q1 | $51K | Buy |
+2,478
| New | +$56.9K | ﹤0.01% | 2379 |
|
|
2018
Q2 | – | Sell |
-633
| Closed | -$22K | – | 2532 |
|
|
2018
Q1 | $22K | Hold |
633
| – | – | ﹤0.01% | 2384 |
|
|
2017
Q4 | $27K | Buy |
633
+482
| +319% | +$20.6K | ﹤0.01% | 2328 |
|
|
2017
Q3 | $6K | Hold |
151
| – | – | ﹤0.01% | 2484 |
|
|
2017
Q2 | $6K | Sell |
151
-357
| -70% | -$15.8K | ﹤0.01% | 2486 |
|
|
2017
Q1 | $28K | Sell |
508
-59
| -10% | -$3.07K | ﹤0.01% | 2154 |
|
|
2016
Q4 | $30K | Sell |
567
-24,471
| -98% | -$1.39M | ﹤0.01% | 2079 |
|
|
2016
Q3 | $1.52M | Buy |
25,038
+167
| +0.7% | +$10.4K | 0.02% | 683 |
|
|
2016
Q2 | $1.64M | Buy |
24,871
+953
| +4% | +$60.5K | 0.02% | 585 |
|
|
2016
Q1 | $1.36M | Buy |
23,918
+6,756
| +39% | +$760K | 0.02% | 637 |
|
|
2015
Q4 | $4.04M | Buy |
17,162
+910
| +6% | +$198K | 0.05% | 362 |
|
|
2015
Q3 | $2.57M | Buy |
16,252
+16,222
| +54,073% | +$4.59M | 0.04% | 446 |
|
|
2015
Q2 | $11K | Hold |
30
| – | – | ﹤0.01% | 1311 |
|
|
2015
Q1 | $12K | Buy |
+30
| New | +$10.7K | ﹤0.01% | 1268 |
|
|
2014
Q3 | – | Sell |
-2,000
| Closed | -$490K | – | 969 |
|
|
2014
Q2 | $490K | Buy |
+2,000
| New | +$452K | 0.01% | 732 |
|
Other funds holding CLDX
KCM
DTC
LGM
Zurich Cantonal Bank's CLDX Position: Q2 2026 in Review
Zurich Cantonal Bank held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 30,677 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1472.
Zurich Cantonal Bank first reported a position in CLDX in Q2 2014 and has held it in 35 quarters since. The position peaked at $4.04M in Q4 2015. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.
- Zurich Cantonal Bank held 30,677 shares of Celldex Therapeutics worth $1.14M as of Q2 2026.
- Zurich Cantonal Bank left its Celldex Therapeutics share count unchanged in Q2 2026.
- Celldex Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1472 holding.
- Zurich Cantonal Bank first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 35 quarters since.
- Zurich Cantonal Bank's Celldex Therapeutics position peaked at $4.04M in Q4 2015.
- 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.